? PROTEOMICS SHARED RESOURCE (PSR) The PSR provides expertise and access to state-of-the-art instrumentation for proteomics experiments. The PSR is embedded within the OSU Campus Chemical Instrument Center, offering competitive pricing and exceptional service by leveraging generous support from the Office of Research and Colleges, and grants from the NIH. During the last review, the PSR was rated Outstanding as part of the Analytics Shared Resource Group, with three addressable comments to reduce turn-around time, a perceived drop in percent users actually due to an increase of non-cancer users as an OSU facility, and perceived duplicative services. Major services include: 1) consultation for sample preparation, MS experiment design, data analysis, and timelines; 2) protein identification using state-of-the-art MS on a variety of sample matrices; 3) in depth protein characterization including, but not limited to, post-translational modifications, protein variant/mutations, protein truncation sites detection, alternate splice form detection, de novo protein sequencing, protein cross-linking, and protein-protein interactions; 4) protein quantification using label-free (spectral counts and/or relative intensity) or stable isotope label techniques (SILAC or ITRAQ/TMT), quantitative MALDI tissue imaging, and targeted mass spectrometry; and 5) data analysis provided with the BISR using commercial and in-house developed software platforms. Major equipment has been enhanced in the past 5 years through three NIH S10 grants and a funded P41 Resource Center for methods development.
PSR Specific Aims are to: 1) provide advanced mass spectrometry-based proteomics services; 2) provide innovative proteomic data analytics and bioinformatics platforms to facilitate user interpretation; and, 3) provide consultation on experimental design and training on self-operated MS instruments. Over the current funding cycle, the PSR provided key services in support of 44 publications (5 > 10 impact factor), 380 users, and 8 NCI grants, including 1 K22, 1 P01, 4 R01s, 1 R33 and 1 U01. The PSR is critical to the OSUCCC research priorities of immuno-oncology, translational genomics, cancer engineering and cancer prevention and survivorship. Advanced analytical platforms allow researchers to discover novel differentially expressed proteins in serum, urine, BAL fluid, saliva, frozen tissues, formalin fixed tissues, cell culture media, and cell lysates. Given the robust OSUCCC recruitment, demand for services and new technologies will increase. The GSR will expand its staff, instrumentation and services before capacity is reached. To address this, planned new services are being implemented or expanded (informatics services with BISR, capillary electrophoresis and ion mobility methods, tissue imaging, and structural biology using native MS, as developed by a P41 Resource grant). Over the next funding period, the PSR will be a member of the Immune Monitoring and Discovery Platform. The annual budget of the PSR is $1,993,101, yet the CCSG request is $158,381. Thus, the PSR leverages extensive institutional support and seeks only 7.9% support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090017
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Lehmann, Vicky; Nahata, Leena; Ferrante, Amanda C et al. (2018) Fertility-Related Perceptions and Impact on Romantic Relationships Among Adult Survivors of Childhood Cancer. J Adolesc Young Adult Oncol 7:409-414
Dix, David B; Seibel, Nita L; Chi, Yueh-Yun et al. (2018) Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol 36:1564-1570
Kohnken, Rebecca; Wen, Jing; Mundy-Bosse, Bethany et al. (2018) Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma. Blood 131:771-781
Londhe, Priya; Yu, Peter Y; Ijiri, Yuichi et al. (2018) Classical NF-?B Metabolically Reprograms Sarcoma Cells Through Regulation of Hexokinase 2. Front Oncol 8:104
Valenciaga, Anisley; Saji, Motoyasu; Yu, Lianbo et al. (2018) Transcriptional targeting of oncogene addiction in medullary thyroid cancer. JCI Insight 3:
Kiss, Daniel L; Baez, William D; Huebner, Kay et al. (2018) Loss of fragile histidine triad (Fhit) protein expression alters the translation of cancer-associated mRNAs. BMC Res Notes 11:178
Vasu, Sumithira; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv 2:1645-1650
Denton, Nicholas L; Chen, Chun-Yu; Hutzen, Brian et al. (2018) Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment. Mol Ther Oncolytics 11:62-74
Krasnick, Bradley A; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium. J Surg Oncol 117:363-371
Badawi, Mohamed; Kim, Jihye; Dauki, Anees et al. (2018) CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128. Oncotarget 9:26032-26045

Showing the most recent 10 out of 2602 publications